Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07)
| Autor: | Jens Huober, Anita Giobbie-Hurder, J. Lüthi, G. Berthod, A. Schönenberger, O. Pagani, M. Simcock, Peter Brauchli, C. Genton, Khalil Zaman, S. Aebi, Beat Thürlimann |
|---|---|
| Přispěvatelé: | Swiss Group for Clinical Cancer Research (SAKK) |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
Oncology
musculoskeletal diseases medicine.medical_specialty Bone density medicine.drug_class medicine.medical_treatment Osteoporosis Aged Aged 80 and over Antineoplastic Combined Chemotherapy Protocols/adverse effects Antineoplastic Combined Chemotherapy Protocols/therapeutic use Bone Density/drug effects Breast Neoplasms/drug therapy Female Hip/pathology Hip/radiography Humans Lumbar Vertebrae/pathology Lumbar Vertebrae/radiography Middle Aged Multivariate Analysis Nitriles/administration & dosage Osteoporosis/chemically induced Osteoporosis/radiography Postmenopause Randomized Controlled Trials as Topic Retrospective Studies Tamoxifen/administration & dosage Triazoles/administration & dosage 610 Medicine & health Breast Neoplasms Breast cancer Bone Density Internal medicine Antineoplastic Combined Chemotherapy Protocols Nitriles medicine Bone mineral Hip Lumbar Vertebrae Aromatase inhibitor business.industry Letrozole Hormone replacement therapy (menopause) Hematology Triazoles medicine.disease Radiography Tamoxifen business medicine.drug |
| Zdroj: | Annals of Oncology, vol. 23, no. 6, pp. 1474-1481 Zaman, K; Thürlimann, B; Huober, J; Schönenberger, A; Pagani, O; Lüthi, J; Simcock, M; Giobbie-Hurder, A; Berthod, G; Genton, C; Brauchli, P; Aebi, S (2012). Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07). Annals of oncology, 23(6), pp. 1474-1481. Oxford University Press 10.1093/annonc/mdr448 |
| DOI: | 10.1093/annonc/mdr448 |
| Popis: | BACKGROUND The risk of osteoporosis and fracture influences the selection of adjuvant endocrine therapy. We analyzed bone mineral density (BMD) in Swiss patients of the Breast International Group (BIG) 1-98 trial [treatment arms: A, tamoxifen (T) for 5 years; B, letrozole (L) for 5 years; C, 2 years of T followed by 3 years of L; D, 2 years of L followed by 3 years of T]. PATIENTS AND METHODS Dual-energy X-ray absorptiometry (DXA) results were retrospectively collected. Patients without DXA served as control group. Repeated measures models using covariance structures allowing for different times between DXA were used to estimate changes in BMD. Prospectively defined covariates were considered as fixed effects in the multivariable models. RESULTS Two hundred and sixty-one of 546 patients had one or more DXA with 577 lumbar and 550 hip measurements. Weight, height, prior hormone replacement therapy, and hysterectomy were positively correlated with BMD; the correlation was negative for letrozole arms (B/C/D versus A), known osteoporosis, time on trial, age, chemotherapy, and smoking. Treatment did not influence the occurrence of osteoporosis (T score < -2.5 standard deviation). CONCLUSIONS All aromatase inhibitor regimens reduced BMD. The sequential schedules were as detrimental for bone density as L monotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|